Ester M Hammond
Overview
Explore the profile of Ester M Hammond including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
5799
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goncalves T, Cunniffe S, Ma T, Mattis N, Rose A, Kent T, et al.
Nucleic Acids Res
. 2025 Feb;
53(4).
PMID: 39970292
The alternative lengthening of telomeres (ALT) pathway is a telomerase-independent mechanism for immortalization in cancer cells and is commonly activated in low-grade and high-grade glioma, as well as osteosarcoma. The...
2.
Goncalves T, Cunniffe S, Ma T, Mattis N, Rose A, Kent T, et al.
Nucleic Acids Res
. 2025 Feb;
53(4).
PMID: 39921567
The alternative lengthening of telomeres (ALT) pathway is a telomerase-independent mechanism for immortalization in cancer cells and is commonly activated in low-grade and high-grade glioma, as well as osteosarcoma. The...
3.
Estephan H, Tailor A, Parker R, Kreamer M, Papandreou I, Campo L, et al.
EMBO J
. 2025 Jan;
44(3):903-922.
PMID: 39753950
Hypoxia is a common feature of solid tumors that has previously been linked to resistance to radiotherapy and chemotherapy, and more recently to immunotherapy. In particular, hypoxic tumors exclude T...
4.
Kambe G, Kobayashi M, Ishikita H, Koyasu S, Hammond E, Harada H
Biochem Biophys Res Commun
. 2024 Aug;
733:150604.
PMID: 39197198
Hypoxia-inducible factor 1 (HIF-1), recognized as a master transcription factor for adaptation to hypoxia, is associated with malignant characteristics and therapy resistance in cancers. It has become clear that cofactors...
5.
Twigger S, Dominguez B, Porto V, Hacker L, Chalmers A, Breckenridge R, et al.
Redox Biol
. 2024 Aug;
76:103326.
PMID: 39180984
Regions of hypoxia occur in most solid tumours and are known to significantly impact therapy response and patient prognosis. Ag5 is a recently reported silver molecular cluster which inhibits both...
6.
Marsh J, Hacker L, Huang S, Boulet M, White J, Martin L, et al.
Dalton Trans
. 2024 Aug;
53(35):14811-14816.
PMID: 39169877
Hypoxia (low-oxygen) is one of the most common characteristics of solid tumours. Exploiting tumour hypoxia to reductively activate Pt(IV) prodrugs has the potential to deliver toxic Pt(II) selectively and thus...
7.
Tosun C, Wallabregue A, Mallerman M, Phillips S, Edwards C, Conway S, et al.
JACS Au
. 2023 Nov;
3(11):3237-3246.
PMID: 38034969
Regions of hypoxia occur in most tumors and are a predictor of poor patient prognosis. Hypoxia-activated prodrugs (HAPs) provide an ideal strategy to target the aggressive, hypoxic, fraction of a...
8.
Ma T, Worth K, Maher C, Ng N, Beghe C, Gromak N, et al.
Nucleic Acids Res
. 2023 Oct;
51(21):11584-11599.
PMID: 37843099
Hypoxia is a common feature of solid tumors and is associated with poor patient prognosis, therapy resistance and metastasis. Radiobiological hypoxia (<0.1% O2) is one of the few physiologically relevant...
9.
Celora G, Bader S, Hammond E, Maini P, Pitt-Francis J, Byrne H
J Theor Biol
. 2023 Jun;
571:111507.
PMID: 37286445
No abstract available.
10.
Boulet M, Bolland H, Hammond E, Sedgwick A
J Am Chem Soc
. 2023 Jun;
145(24):12998-13002.
PMID: 37283248
Platinum(IV) anticancer agents have demonstrated the potential to overcome the limitations associated with the widely used Pt(II) chemotherapeutics, cisplatin, carboplatin, and oxaliplatin. In order to identify therapeutic scenarios where this...